000123966 001__ 123966
000123966 005__ 20240319081028.0
000123966 0247_ $$2doi$$a10.3390/pharmaceutics14122744
000123966 0248_ $$2sideral$$a132439
000123966 037__ $$aART-2022-132439
000123966 041__ $$aeng
000123966 100__ $$aGaglio, Salvatore Calogero
000123966 245__ $$aEmbedding Biomimetic Magnetic Nanoparticles Coupled with Peptide AS-48 into PLGA to Treat Intracellular Pathogens
000123966 260__ $$c2022
000123966 5060_ $$aAccess copy available to the general public$$fUnrestricted
000123966 5203_ $$aAmong the strategies employed to overcome the development of multidrug-resistant bacteria, directed chemotherapy combined with local therapies (e.g., magnetic hyperthermia) has gained great interest. A nano-assembly coupling the antimicrobial peptide AS-48 to biomimetic magnetic nanoparticles (AS-48-BMNPs) was demonstrated to have potent bactericidal effects on both Gram-positive and Gram-negative bacteria when the antimicrobial activity of the peptide was combined with magnetic hyperthermia. Nevertheless, intracellular pathogens remain challenging due to the difficulty of the drug reaching the bacterium. Thus, improving the cellular uptake of the nanocarrier is crucial for the success of the treatment. In the present study, we demonstrate the embedding cellular uptake of the original nano-assembly into THP-1, reducing the toxicity of AS-48 toward healthy THP-1 cells. We optimized the design of PLGA[AS-48-BMNPs] in terms of size, colloidal stability, and hyperthermia activity (either magnetic or photothermal). The stability of the nano-formulation at physiological pH values was evaluated by studying the AS-48 release at this pH value. The influence of pH and hyperthermia on the AS-48 release from the nano-formulation was also studied. These results show a slower AS-48 release from PLGA[AS-48-BMNPs] compared to previous nano-formulations, which could make this new nano-formulation suitable for longer extended treatments of intracellular pathogens. PLGA[AS-48-BMNPs] are internalized in THP-1 cells where AS-48 is liberated slowly, which may be useful to treat diseases and prevent infection caused by intracellular pathogens. The treatment will be more efficient combined with hyperthermia or photothermia.
000123966 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000123966 590__ $$a5.4$$b2022
000123966 592__ $$a0.795$$b2022
000123966 591__ $$aPHARMACOLOGY & PHARMACY$$b50 / 278 = 0.18$$c2022$$dQ1$$eT1
000123966 593__ $$aPharmaceutical Science$$c2022$$dQ1
000123966 594__ $$a6.9$$b2022
000123966 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000123966 700__ $$aJabalera, Ylenia
000123966 700__ $$aMontalbán-López, Manuel
000123966 700__ $$0(orcid)0000-0002-3027-2408$$aMillán-Placer, Ana Cristina$$uUniversidad de Zaragoza
000123966 700__ $$aLázaro-Callejón, Marina
000123966 700__ $$aMaqueda, Mercedes
000123966 700__ $$aCarrasco-Jimenez, María Paz
000123966 700__ $$aLaso, Alejandro
000123966 700__ $$0(orcid)0000-0003-2076-844X$$aAínsa, José A.$$uUniversidad de Zaragoza
000123966 700__ $$aIglesias, Guillermo R.
000123966 700__ $$aPerduca, Massimiliano
000123966 700__ $$aLópez, Concepción Jiménez
000123966 7102_ $$11011$$2630$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Microbiología
000123966 773__ $$g14, 12 (2022), 2744 [20 pp.]$$pPharmaceutics$$tPharmaceutics$$x1999-4923
000123966 8564_ $$s3487186$$uhttps://zaguan.unizar.es/record/123966/files/texto_completo.pdf$$yVersión publicada
000123966 8564_ $$s2778161$$uhttps://zaguan.unizar.es/record/123966/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000123966 909CO $$ooai:zaguan.unizar.es:123966$$particulos$$pdriver
000123966 951__ $$a2024-03-18-16:56:10
000123966 980__ $$aARTICLE